Intellia Therapeutics, Inc. $NTLA Stock Position Reduced by Interchange Capital Partners LLC

Interchange Capital Partners LLC cut its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 10.1% during the second quarter, HoldingsChannel.com reports. The firm owned 10,665 shares of the company’s stock after selling 1,202 shares during the period. Interchange Capital Partners LLC’s holdings in Intellia Therapeutics were worth $100,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. HighTower Advisors LLC grew its position in Intellia Therapeutics by 8.2% during the first quarter. HighTower Advisors LLC now owns 16,921 shares of the company’s stock valued at $120,000 after purchasing an additional 1,282 shares in the last quarter. Harbour Investments Inc. lifted its stake in Intellia Therapeutics by 27.2% in the second quarter. Harbour Investments Inc. now owns 6,633 shares of the company’s stock valued at $62,000 after acquiring an additional 1,419 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Intellia Therapeutics by 56.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock valued at $33,000 after acquiring an additional 1,655 shares during the last quarter. Arete Wealth Advisors LLC lifted its stake in Intellia Therapeutics by 21.8% in the first quarter. Arete Wealth Advisors LLC now owns 12,512 shares of the company’s stock valued at $89,000 after acquiring an additional 2,240 shares during the last quarter. Finally, LMG Wealth Partners LLC lifted its stake in Intellia Therapeutics by 28.4% in the first quarter. LMG Wealth Partners LLC now owns 14,285 shares of the company’s stock valued at $102,000 after acquiring an additional 3,157 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on NTLA. JMP Securities upgraded shares of Intellia Therapeutics from a “market perform” rating to a “market outperform” rating and set a $33.00 target price for the company in a research note on Monday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Saturday. Chardan Capital reduced their target price on shares of Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Citizens Jmp upgraded shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $33.00 target price for the company in a research note on Monday, October 6th. Finally, Guggenheim reiterated a “buy” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research note on Wednesday, August 13th. Thirteen research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Intellia Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $28.47.

Insider Buying and Selling at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 1,871 shares of the company’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the transaction, the chief accounting officer directly owned 55,266 shares in the company, valued at $960,523.08. This represents a 3.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director William J. Chase bought 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were bought at an average price of $10.03 per share, with a total value of $1,003,000.00. Following the completion of the purchase, the director owned 134,693 shares in the company, valued at approximately $1,350,970.79. The trade was a 288.24% increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.10% of the stock is owned by corporate insiders.

Intellia Therapeutics Trading Down 1.1%

Shares of Intellia Therapeutics stock opened at $25.60 on Monday. The firm has a fifty day simple moving average of $16.82 and a 200-day simple moving average of $12.13. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $28.25. The stock has a market capitalization of $2.75 billion, a price-to-earnings ratio of -5.46 and a beta of 2.37.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.04. The business had revenue of $14.25 million during the quarter, compared to analysts’ expectations of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. Intellia Therapeutics’s revenue for the quarter was up 104.3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.52) earnings per share. As a group, research analysts predict that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.